Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 GlobeNewswire November 10, 2025 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it […]
Aqua Metals and Westwin Elements Sign LOI for U.S.-Produced Nickel Carbonate Supply Agreement outlines plans for one of the first domestic sources of battery-grade nickel carbonate GlobeNewswire November 10, 2025 RENO, Nev., Nov. 10, 2025 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable battery metals recycling and refining, today announced a
(NASDAQ:ATYR), SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual
Madrigal Presents New Data Demonstrating Rezdiffra(R) (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis GlobeNewswire November 10, 2025 Rezdiffra(R) treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures
(NASDAQ:KYTX), EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, November 17,
Disguise and Aniplex Announce Expanded Licensing Agreement for Demon Slayer: Kimetsu no Yaiba Costumes and Accessories GlobeNewswire November 10, 2025 POWAY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Disguise, Inc., the global costume division of leading toy and consumer products company JAKKS Pacific, Inc. (NASDAQ: JAKK), today announced the expansion of its multi-year licensing agreement
(NASDAQ:GALT), New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kg Using established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experienced greater-than or equal to30% or greater-than or equal to5 kPa increases in liver stiffness (LSM) by FibroScan(R) compared with placebo, indicating
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 10, 2025 REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such
(NASDAQ:ALGS), SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations, including one oral presentation, at the American Association for the Study of Liver Disease's
20% of Software Budgets Wasted on Unnecessary Business Complexity, Freshworks Survey Finds New research identifies the “growth tax” on companies due to enterprise software-induced complexity, which drains millions of dollars and costs employees nearly a full workday each week in lost productivity GlobeNewswire November 10, 2025 SAN MATEO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) —